Hypertension, anti-hypertensive therapy and neoplasia

Current Pharmaceutical Design

Volumn 13, Issue 25, 2007, Pages 2539-2544

  Goon, Patrick K Y ^a,b   Stonelake, Paul S ^b   Lip, Gregory Y H ^a  

^a UNIVERSITY DEPARTMENT OF MEDICINE   (United Kingdom)

^b RUSSELLS HALL HOSPITAL   (United Kingdom)

Author keywords

Anti hypertensive; Cancer; Hypertension

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; BENDROFLUMETHIAZIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; DIHYDROPYRIDINE DERIVATIVE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FELODIPINE; HYDROCHLOROTHIAZIDE; PLACEBO; POTASSIUM SPARING DIURETIC AGENT; PROPRANOLOL; RESERPINE; THIAZIDE DIURETIC AGENT;

ANTIHYPERTENSIVE ACTIVITY; ANTIHYPERTENSIVE THERAPY; ANTINEOPLASTIC ACTIVITY; BLOOD PRESSURE; BREAST CANCER; CANCER; CANCER INCIDENCE; CANCER MORTALITY; CANCER RISK; CARCINOGENESIS; CLINICAL TRIAL; COLON CANCER; COMBINATION CHEMOTHERAPY; CONGESTIVE HEART FAILURE; DISEASE ASSOCIATION; ENDOMETRIUM CANCER; HUMAN; HYPERTENSION; KIDNEY CARCINOMA; LIVER CANCER; LOW DRUG DOSE; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SYSTOLIC HYPERTENSION; TREATMENT DURATION;

ANIMALS; ANTIHYPERTENSIVE AGENTS; HUMANS; HYPERTENSION; NEOPLASMS;

EID: 34548722791     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161207781663073     Document Type: Review

References (90)

1. Kakar P, Lip GY. Towards understanding the aetiology and pathophysiology of human hypertension:wHere are we now? J Hum Hypertens 2006; 20(11): 833-6.
2. Kakar P; Lip GY. Towards improving the clinical assessment and management of human hypertension: An overview from this Journal. J Hum Hypertens 2006;20(12):913-6.
3. Goon PK, Messerli FH, Lip GY. Hypertension and breast cancer. an association revisited? J Hum Hypertens 2006; 20(10): 722-4.
4. Grossman E, Messerli FH, Boyko V, Goldbourt U. Is there an association between hypertension and cancer mortality? Am J Med 2001; 112(6): 479-86.
5. Dyer AR, Stamler J, Berkson DM, Lindberg HA, Stevens E. High blood-pressure: A risk factor for cancer mortality? Lancet 1975; 1(7915): 1051-6.
6. Taylor JO, Cornoni-Huntley J, Curb JD, Manton KG, Ostfeld AM, Scherr P, et al. Blood pressure and mortality risk in the elderly. Am J Epidemiol 1991; 134(5): 489-501.
7. Clausen J, Jensen G. Blood pressure and mortality: An epidemiological survey with 10 years follow-up: J Hum Hypertens 1992; 6(1): 53-9.
8. Batty GD, Shipley MJ, Marmot MG, Davey Smith G; Whitehall Study. Blood pressure and site-specific cancer mortality: Evidence from the original Whitehall study. Br J Cancer 2003; 89(7): 1243-7.
9. Castellsague X, Munoz N, De Stefani E, Victora CG, Castelletto R, Rolon PA, et al. Independent and joint effects of tobacco smoking and alcohol drinking on the risk of esophageal cancer in men and women. Int J Cancer 1999; 82(5): 657-64.
10. Calle EE, Thun MJ. Obesity and cancer. Oncogene 2004; 23(38): 6365-78
11. Edwards BK, Howe HL, Ries LA, Thun MJ, Rosenberg HM, Yancik R, et al. Annual report to the nation on the status of cancer, 1973-1999, featuring implications of age and aging on U.S. cancer burden. Cancer 2002; 94(10): 2766-92.
12. Chow WH, Gridley G, Fraumeni JF Jr, Jarvhohn B. Obesity, hypertension, and the risk of kidney cancer in men. N Engl J Med 2000; 343(18): 1305-11.
13. Flaherty KT, Fuchs CS, Colditz GA, Stampfer MJ, Speizer FE, Willett WC, et al. A prospective study of body mass index, hypertension, and smoking and the risk of renal cell carcinoma (United States). Cancer Causes Control 2005; 16(9): 1099-106.
14. Rosenberg L, Stephenson WP, Rao RS, Palmer JR, Strom BL, Shapiro S. The diagnosis of renal cell cancer in relation to hypertension (United States). Cancer Causes Control 1998; 9(6): 611-4.
15. Choi MY, Jee SH, Sull JW, Nam CM. The effect of hypertension on the risk for kidney cancer in Korean men. Kidney hit 2005; 67(2): 647-52.
16. Heath CW Jr, Lally CA, Calle EE, McLaughlin JK, Thun MJ. Hypertension, diuretics, and antihypertensive medications as possible risk factors for renal cell cancer. Am J Epidemiol 1997; 145(7): 607-13.
17. Soler M, Chatenoud L, Negri E, Parazzini F, Franceschi S, la Vecchia C. Hypertension and hormone-related neoplasms in women. Hypertension 1999; 34(2): 320-5.
18. Largent JA, McEligot AJ, Ziogas A, Reid C, Hess J, Leighton N, et al. Hypertension, diuretics and breast cancer risk. J Hum Hypertens 2006; 20(10): 727-32.
19. Parazzini F, Negri E, La Vecchia C, Bruzzi P, Decarli A. Population attributable risk for endometrial cancer in northern Italy. Eur J Cancer Clin Oncol 1989; 25(10): 1451-6.
20. Weiderpass E, Persson I, Adami HO, Magnusson C, Lindgren A, Baron JA. Body size in different periods of life, diabetes mellitus, hypertension, and risk of postmenopausal endometrial cancer (Sweden). Cancer Causes Control 2000; 11(2):185-92.
21. Land CE, Hayakawa N, Machado SG, Yamada Y, Pike MC, Akiba S, et al. A case-control interview study of breast cancer among Japanese A-bomb survivors. II. Interactions with radiation dose. Cancer Causes Control 1994; 5(2): 167-76.
22. de Waard F, Baanders-van Halewijn EA.A prospective study in general practice on breast-cancer risk in postmenopausal women. Int J Cancer 1974; 14(2): 153-60.
23. Khaw KT, Barrett-Connor E. Systolic blood pressure and cancer mortality in an elderly population. Am J Epidemiol 1984; 120(4); 550-8.
24. Wannamethee G, Shaper AG. Blood pressure and cancer in middle-aged British men. Int J Epidemiol 1996; 25(1): 22-31.
25. Lee SY, Kim MT, Jee SH, Im JS. Does hypertension increase mortality risk from lung cancer? A prospective cohort study on smoking, hypertension and lung cancer risk among Korean men. J Hypertens 2002; 20(4): 617-22.
26. Lindgren AM, Nissinen AM, Tuomilehto JO, Pukkala E. Cancer pattern among hypertensive patients in North Karelia, Finland. J Hum Hypertens 2005; 19(5): 373-9.
27. Staessen JA, Fagard R, Thijs L, Celis H, Arabidze GG, Birkenhager WH, et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet 1997; 350(9080): 757-64.
28. Lindholm LH, Anderson H, Ekbom T, Hansson L, Lanke J, Dahlof B, et al. Relation between drug treatment and cancer in hypertensives in the Swedish Trial in Old Patients with Hypertension 2: A 5-year, prospective, randomised, controlled trial. Lancet 2001; 358(9281): 539-44.
29. Dahlof B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, et al. ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): A multicentre randomised controlled trial. Lancet 2005; 366(9489): 895-906.
30. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Collaborative Research Group, Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT), JAMA 2000; 283: 1967-1975.
31. Kjeldsen SE, Dahlof B, Devereux RB, Julius S, Aurup P, Edelman J, et al. LIFE (Losartan Intervention for Endpoint Reduction) Study Group. Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: A Losartan Intervention for Endpoint Reduction (LIFE) substudy. JAMA 2002; 288(12): 1491-8.
32. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group. JAMA 1991; 265(24):3255-64.
33. Williams B, Poulter NR, Brown MJ, Davis M, McInnes GT, Potter JF, et al. BHS guidelines working party, British Hypertension Society guidelines for hypertension management 2004 (BHS-IV): Summary. BMJ 2004; 328(7440): 634-40.
34. British Hypertension Society and National Institute for Clinical Excellence (NICE) Guidelines: The management of hypertension in adults in primary care (June 2006 update). http://www.nice. org.uk/ page.aspx?o=335988
35. Carlsen JE, Kober L, Torp-Pedersen C, Johansen P. Relation between dose of bendrofluazide, antihypertensive effect, and adverse biochemical effects. BMJ 1990; 300(6730): 975-8.
36. Weinmann S, Glass AG, Weiss NS, Psaty BM, Siscovick DS, White E. Use of diuretics and other antihypertensive medications in relation to the risk of renal cell cancer. Am J Epidemiol 1994; 140(9): 792-804.
37. McLaughlin JK, Chow WH, Mandel JS, Mellemgaard A, McCredie M, Lindblad P, et al. International renal-cell cancer study. VIII. Role of diuretics, other anti-hypertensive medications and hypertension. Int J Cancer 1995; 63(2): 216-21.
38. Grossman E, Messerli FH, Goldbourt U. Antihypertensive therapy and the risk of malignancies. Eur Heart J 2001; 22: 1343-52.
39. Yu MC, Mack TM, Hanisch R, Cicioni C, Henderson BE. Cigarette smoking, obesity, diuretic use, and coffee consumption as risk factors for renal cell carcinoma. J Natl Cancer Inst 1986; 77(2): 351-6.
40. Finkle WD, McLaughlin JK, Rasgon SA, Yeoh HH, Low JE. Increased risk of renal cell cancer among women using diuretics in the United States. Cancer Causes Control 1993; 4(6): 555-8.
41. Kreiger N, Marrett LD, Dodds L, Hilditch S, Darlington GA. Risk factors for renal cell carcinoma: Results of a population-based case-control study. Cancer Causes Control 1993; 4(2): 101-10.
42. Hiatt RA, Tolan K, Quesenberry CP Jr. Renal cell carcinoma and thiazide use: A historical, case-control study (California, USA). Cancer Causes Control 1994; 5(4): 319-25.
43. Li CI, Malone KE, Weiss NS, Boudreau DM, Cushing-Haugen KL, Dating JR. Relation between use of antihypertensive medications and risk of breast carcinoma among women ages 65-79 years. Cancer 2003; 98(7), 1504-13.
44. Prineas RJ, Folsom AR, Zhang ZM, Sellers TA, Potter J. Nutrition and other risk factors for renal cell carcinoma in postmenopausal women. Epidemiology 1991; 8(1): 31-6.
45. Grossman E, Messerli FH, Goldbourt U. Does diuretic therapy increase the risk of renal cell carcinoma? Am J Cardiol 1999; 83: 1090-3.
46. MRC trial of treatment of mild hypertension: Principal results, Medical Research Council Working Party. Br Med J (Clin Res Ed): 1985;291(6488):97-104.
47. Lip GYH, Ferner RE. Diuretic therapy for hypertension: A cancer risk? J Hum Hypertens 1999; 13: 421-23.
48. MRC trial of treatment of hypertension in older adults: Principal results. MRC working party. Br Med J 1992; 304: 405-12.
49. Coope JR, Warrender TS. Randomised trial of treatment of hypertension in elderly patients in primary care. Br Med J (Clin Res Ed) 1987; 294(6565): 179.
50. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes:UKPDS 39.UK Prospective Diabetes Study Group. BMJ 1998;317: 713-20.
51. McCredie M, Stewart JH. Risk factors for kidney cancer in New South Wales, Australia. II. Urologic disease, hypertension, obesity, and hormonal factors. Cancer Causes Control 1992; 3(4): 323-31.
52. Rosenberg L, Rao RS, Palmer JR, Strom BL, Stolley PD, Zauber AG, et al. Calcium channel blockers and the risk of cancer. JAMA 1998; 279(13):1000-4.
53. Hole DJ, Hawthorne VM, Isles CG, McGhee SM, Robertson JW, Gillis CR, et al. Incidence of and mortality from cancer in hypertensive patients. BMJ 1993; 306(6878): 609-11.
54. Fletcher AE, Beevers DG, Bulpitt CJ, Coles EC, Dollery CT, Ledingham JG, et al. Cancer mortality and atenolol treatment. BMJ 1993; 306: 622-3.
55. Jick H, Jick S, Derby LE, Vasilakis C, Myers MW, Meier CR. Calcium-channel blockers and risk of cancer. Lancet 1997; 349(9051): 525-8.
56. Tuomilehto J, Rastenyte D, Birkenhager WH, Thijs L, Antikainen R, Bulpitt CJ, et al. Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. Systolic Hypertension in Europe Trial Investigators. Engl J Med 1999; 340(9): 677-84.
57. Pahor M, Guralnik JM, Salive ME, Corti MC, Carbonin P, Havlik RJ. Do calcium channel blockers increase the risk of cancer.? Am J Hypertens 1996; 9(7): 695-9.
58. Pahor M, Guralnik JM, Ferrucci L, Corti MC, Salive ME, Cerhan JR, et al. Calcium-channel blockade and incidence of cancer in aged populations. Lancet 1996; 348(9026): 493-7.
59. Fitzpatrick AL, Daling JR, Furberg CD, Kronmal RA, Weissfeld JL. Use of calcium channel blockers and breast carcinoma risk in postmenopausal women. Cancer 1997; 80(8): 1438-47.
60. Liu L, Zhang Y, Liu G, Li W, Zhang X, Zanchetti A; FEVER Study Group. The Felodipine Event Reduction (FEVER) Study: A randomized long-term placebo-controlled trial in Chinese hypertensive patients. J Hypertens 2005; 23(12): 2157-72.
61. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD Investigators. N Engl J Med 1992; 327(10): 685-91.
62. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, et al., Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy, N Engl J Med 2001; 345: 861-9.
63. Parving HH, Rossing P, Hommel E, Smidt UM. Angiotensin-converting enzyme inhibition in diabetic nephropathy: Ten years experience. Am J Kidney Dis 1995; 26: 99-107.
64. Maschio G, Alberti D, Janin G, Locatelli F, Mann JF, Motolese M, et al. Effect of the angiotensin-converfing-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N Engl J Med 1996; 334(15): 939-45.
65. Lever AF, Hole DJ, Gillis CR, McCallum IR, McInnes GT, MacKinnon PL, et al. Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer? Lancet 1998; 352(9123): 179-84.
66. Friis S, Sorensen HT, Mellemkjaer L, McLaughlin JK, Nielsen GL, Blot WJ, et al. Angiotensin-converting enzyme inhibitors and the risk of cancer: A population-based cohort study in Denmark. Cancer 2001; 92(9): 2462-70.
67. Meier CR, Derby LE, Jick SS, Jick H. Angiotensin-converting enzyme inhibitors, calcium channel blockers, and breast cancer. Arch Intern Med 2000; 160(3): 349-53.
68. Stahl M, Bulpitt CJ, Palmer AJ, Beevers DG, Coles EC, Webster J. Calcium channel blockets, ACE inhibitors, and the risk of cancer in hypertensive patients: A report from the Department of Health Hypertension Care Computing Project (DHCCP). J Hum Hypertens 2000; 14(5): 299-304.
69. De Gasparo M, Catt KJ, Inagami T, Wright JW, Unger T. International union of pharmacology. XXIII. The angiotensin II receptors. Pharmacol Rev 2000; 52: 415-72.
70. Duke LM, Evans RG, Widdop RE. AT2 receptors contribute to acute blood pressure-lowering and vasodilator effects of AT1 receptor antagonism in conscious normotensive but not hypertensive rats. Am J Physiol Heart Circ Physiol 2005; 288(5): H2289-97.
71. Lindberg H, Nielsen D, Jensen BV, Eriksen J, Skovsgaard T. Angiotensin converting enzyme inhibitors for cancer treatment? Acta Oncol 2004; 43(2): 142-52.
72. Abali H, Gullu IH, Engin H, Haznedaroglu IC, Erman M, Tekuzman G. Old antihypertensives as novel antineoplastics:aNgiotensin-I-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists. Medical Hypotheses 2002; 59(3): 344-8.
73. White CM. Angiotensin-converting-enzyme inhibition in heart failure or after myocardial infarction. Am J Health Syst Pharm 2000; 57(Suppl 1): S18-25.
74. Uemura H, Nakaigawa N, Ishiguro H, Kubota Y. Antiproliferative efficacy of angiotensin II receptor blockers in prostate cancer. Curr Cancer Drug Targets 2005; 5(5): 307-23.
75. Lijinsky W, Reuber MD. Pathologic effects of chronic administration of hydrochlorothiazide, with and without sodium nitrite, to F344 rats. Toxicol Ind Health 1987; 3(3): 413-22.
76. Loffing J, Loffing-Cueni D, Hegyi I, Kaplan MR, Hebert SC, Le Hir M, et al. Thiazide treatment of rats provokes apoptosis in distal tubule cells. Kidney Int 1996; 50(4): 1180-90.
77. Gago-Dominguez M, Castelao J. Lipid peroxidation and renal cell carcinoma: Further supportive evidence and new mechanistic insights. Free Radic Biol Med 2006; 40(4): 721-33.
78. Harnet P. Cancer and hypertension: A potential for crosstalk? J Hypertension 1997; 15: 1573-77.
79. Cardani R, Ragnotti G, Radaelli G, Zavanella T. Influence of beta-adrenergic antagonists on cell proliferation rates in the kidney of untreated and diethylnitrosamine-treated male F344 rats. Chem Biol Interact 1999; 118(3): 217-31.
80. Connor J, Sawczuk IS, Benson MC, Tomashefsky P, O'Toole KM, Olsson CA, et al. Calcium channel antagonists delay regression of androgen-dependent tissues and suppress gene activity associated with cell death. Prostate 1988; 13(2): 119-30.
81. Ray SD, Kamendulis LM, Gurule MW, Yorkin RD, Corcoran GB. Ca2+ antagonists inhibit DNA fragmentation and toxic cell death induced by acetaminophen. FASEB J 1993; 7(5): 453-63.
82. Taylor JM, Simpson RU. Inhibition of cancer cell growth by calcium channel antagonists in the athymic mouse. Cancer Res 1992 52(9): 2413-8.
83. Yoshida J, Ishibashi T, Nishio M. Antitumor effects of amlodipine, a Ca2+ channel blocker, on human epidermoid carcinoma A431 cells in vitro and in vivo.Eur J Pharmacol 2004; 492(2-3): 103-12.
84. Lee YS, Sayeed MM, Wurster RD. Inhibition of cell growth and intracellular Ca2+ mobilization in human brain tumor cells by Ca2+ channel antagonists. Mol Chem Neuropathol 1994; 22(2): 81-95.
85. Jensen RL, Origitano TC, Lee YS, Weber M, Wurster RD. In vitro growth inhibition of growth factor-stimulated meningioma cells by calcium channel antagonists. Neurosurgery 1995; 36(2): 365-73.
86. Jensen RL, Wurster RD. Calcium channel antagonists inhibit growth of subcutaneous xenograft meningiomas in nude mice. Surg Neurol 2001; 55(5): 275-83.
87. Fryzek JP, Poulsen AH, Lipworth L, Pedersen L, Norgaard M, McLaughlin JK, et al. A Cohort Study of Antihypertensive Medication Use and Breast Cancer Among Danish Women. Breast Cancer Res Treat 2006; 97(3): 231-6.
88. Biondi C, Pavan B, Lunghi L, Fiorini S, Vesce F. The role and modulation of the oxidative balance in pregnancy. Curr Pharm Des 2005; 11(16): 2075-89.
89. Nadar SK, Tayebjee MH, Messerli F, Lip GY. Target organ damage in hypertension: Pathophysiology and implications for drug therapy. Curr Pharm Des 2006; 12(13): 1581-92.
90. Webster WS, Howe AM, Abela D, Oake DJ, The relationship between cleft lip, maxillary hypoplasia, hypoxia and phenytoin. Curr Pharm Des 2006; 12(12): 1431-48.